LGC acquires MBH Analytical

Located in Barnet, north London, MBH was founded in 1973 and is certified to ISO 9001:2015.
Its RMs are used globally for quality control testing and material validation, including positive materials identification testing, in a wide range of end-markets, including the aerospace, automotive, metal manufacturing and electronics markets. MBH also distributes a range of third party metal alloy RMs.
The deal sees LGC substantially increase the breadth of its metal alloy RMs portfolio, thereby strengthening its differentiated position as a manufacturer of RMs for that segment.
Euan O’Sullivan, Managing Director, Standards, LGC, said: “We are delighted to be adding MBH’s range of more than 900 mainly unique products to our portfolio and their deep metal alloy development capabilities to our team."
"MBH’s products are a great complement to LGC’s and the combination enables us to provide our customers with a portfolio of unrivalled breadth for all of their metal alloy RM requirements.“
Sign up for your free email newsletter
David Wood and Chris Eveleigh, owners, MBH, said: “We are pleased to take this next step in the life of MBH Analytical. Joining LGC will provide the support required to meet the challenges ahead in continuing to produce world class certified reference materials for the growing analytical community.”
Looking for chemical products? Let suppliers reach out to you!
2026-06-24
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Platinum Chemotherapy Shortages Expose the Fragility of Essential API Supply
-
Lilly’s U.S. API Investment Highlights a New Phase of Pharma Supply Localization
-
Novo Nordisk Faces $46 Billion Windfall Threatened by Wegovy Missteps and Eli Lilly’s Rise
-
Lupin Secures Tentative U.S. Approval for Its Multiple Sclerosis Tablet
-
NATO Fund Invests $35 Million in Biotech Startup to Counter Biological Threats
-
Biological E Partners with Recbio to Bring HPV9 Vaccine to India and Global Markets
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Pill That Could Swallow the Needle: Novo Nordisk Launches Oral Wegovy in U.S. Weight-Loss Revolution
Recommend Reading
-
The $6 Billion Gold Rush: Generic Semaglutide Set to Reshape Global Pharma After Patent Cliff
-
Over 100 Foreign Pharma Executives Join Chinese Firms in 5 Years Industry Faces Key Challenges
-
Merck’s New CMV Drug Approved in China Targets Nearly 40000 HSCT Patients
-
FDA Approves Datopotamab Deruxtecan for Second Indication 45 Percent Response Rate in EGFR Mutant Lung Cancer
-
UK Parliament Approves Assisted Dying Bill 7500 Could Seek Euthanasia Annually
-
Behind Starbucks China’s Ownership Change: The Race for Localization and Efficiency
-
Titanium Dioxide: Stuck Between Weak Upside and Limited Downside
-
Canada Exports First LNG Shipment to Asia Marks $29.4 Billion Milestone
-
Supply-Demand Gap Widens, Lithium Carbonate Prices Approach Year-to-Date High
-
Why Did Chemical Raw Materials Unexpectedly Escape the Latest Round of U.S. 301 Tariffs on 60 Economies?